Young child with Doctor

Here in our Media Centre you will find corporate press releases and other useful information for business and financial media

Latest press releases

Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes
19 September 2014
FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
16 September 2014
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
16 September 2014
AstraZeneca to present research from its innovative diabetes portfolio at the 2014 Meeting of the European Association for the Study of Diabetes
10 September 2014
Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine
8 September 2014
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
1 September 2014
AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests
21 August 2014
AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI)
19 August 2014
United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
19 August 2014
AstraZeneca advances tralokinumab to Phase III in severe asthma
14 August 2014
AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients
13 August 2014
AstraZeneca PLC second quarter and half year results 2014
31 July 2014

Fast facts

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.


Sign up to email alerts

Your email address will only be used to provide you with services from AstraZeneca that you requested. You can opt out for email subscriptions any time. Your personal information will not be provided to any third party without your permission.